Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Yogish C. Kudva

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0285-6622; OpenAlex author ID A5061028131; NIH RePORTER profile ID 7873228. Sources: OpenAlex.

Their work

Papers
5
Trials
0
Grants
1
Labs led
1
Collaborators
24
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper, 1 grant

Papers 5

  1. Diabetes secondary to chronic pancreatitis and pancreatic cancer: Observations from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancrea… Co-author DOI 10.1016/j.pan.2026.04.001↗
  2. Pancreatic cancer-related diabetes and type 2 diabetes differ in multiple aspects of glucose homeostasis. Co-author DOI 10.1007/s00125-025-06543-y↗
  3. Comparison of Fasting Human Pancreatic Polypeptide Levels Among Patients With Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, and Type 2 Diabetes Melli… Co-author DOI 10.1097/mpa.0000000000001077↗
  4. Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rational… Co-author DOI 10.1097/mpa.0000000000001168↗
  5. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Co-author DOI 10.1016/s2468-1253(16)30106-6↗

Grants 1

  1. Parallel-group randomized controlled trial of Pioglitazone versus empagliflozin for T3cDM: The PEP-DM Trial R01DK137868↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dhiraj Yadav · 4 shared papers, 1 shared grant, 2016–2026 · strength 1.83
  2. Mark Goodarzi · 4 shared papers, 2016–2026 · strength 0.56
  3. Melena D. Bellin · 4 shared papers, 2016–2026 · strength 0.56
  4. Dana K. Andersen · 4 shared papers, 2016–2026 · strength 0.56
  5. Phil A. Hart · 4 shared papers, 2016–2026 · strength 0.56
  6. Frederico G. S. Toledo · 2 shared papers, 2025–2026 · strength 0.45
  7. Kenneth Cusi · 2 shared papers, 2025–2026 · strength 0.45
  8. Walter Gwang-Up Park · 2 shared papers, 2025–2026 · strength 0.45
  9. Christopher E Forsmark · 2 shared papers, 2016–2026 · strength 0.30
  10. Stephen Jacob Pandol · 2 shared papers, 2016–2026 · strength 0.30
  11. José Serrano · 2 shared papers, 2018–2025 · strength 0.27
  12. Evan L Fogel · 1 shared paper, 2026 · strength 0.24
  13. William E Fisher · 1 shared paper, 2026 · strength 0.24
  14. Randall E. Brand · 1 shared paper, 2025 · strength 0.20
  15. Suresh T. Chari · 2 shared papers, 2016–2018 · strength 0.17
  16. Sajan Jiv Singh Nagpal · 1 shared paper, 2018 · strength 0.12
  17. Aida Habtezion · 2 shared papers, 2016–2018 · strength 0.11
  18. Murray Korc · 2 shared papers, 2016–2018 · strength 0.11
  19. Sudhir Srivastava · 1 shared paper, 2018 · strength 0.06
  20. Ying Yuan · 1 shared paper, 2018 · strength 0.06
  21. Jo Ann Rinaudo · 1 shared paper, 2018 · strength 0.06
  22. Maxim S. Petrov · 1 shared paper, 2018 · strength 0.06
  23. David Clement Whitcomb · 1 shared paper, 2018 · strength 0.06
  24. Zobeida Cruz‐Monserrate · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.